Compared with the general population, solid-organ transplant (SOT) recipients experience a greater incidence and severity of Clostridioides difficile infection (CDI), often leading to significant morbidity and mortality. 1 Risk factors for recurrent CDI such as advanced age, immunocompromised state, and severe infection at initial presentation are well described in SOT recipients. Intestinal transplant recipients (ITRs) are particularly vulnerable to CDI and recurrent CDI,